BACKGROUND: Hepatitis B is the major cause of chronic hepatitis and cirrhosis in Iran. Sanitation and immunization is one of the most effective measures for prevention of the disease which is now widely used in developing countries. However, the immune response to the vaccine varies by age. OBJECTIVES: To determine the effect of zinc sulfate on immune response to hepatitis-B vaccine in elderly. PATIENTS AND METHODS: In a clinical trial on 140 subjects aged ?40 years with a body mass index (BMI) <30 kg/m2, and without any co-morbid disease were recruited. Those who had negative hepatitis B core antibody (102 persons) were randomly allocated to two groups. The trial group received hepatitis B vaccine plus 200 mg zinc sulfate daily for 30 days and the control group received vaccine plus placebo. RESULTS: 52 of 102 people were female (51%). The two studied groups were comparable in terms of age, gender, and smoking habits. The mean antibody production in the intervention and control groups was 116.93 and 157.37 mIU/mL, respectively (p=0.22). No statistical differences were observed between the two groups in terms of proportion of people who were protected after vaccination (26.0% and 36.5% in people with and without zinc, respectively). CONCLUSIONS: This study revealed that zinc sulfate has no effect in level of immunity among elderly.
RCT Entities:
BACKGROUND:Hepatitis B is the major cause of chronic hepatitis and cirrhosis in Iran. Sanitation and immunization is one of the most effective measures for prevention of the disease which is now widely used in developing countries. However, the immune response to the vaccine varies by age. OBJECTIVES: To determine the effect of zinc sulfate on immune response to hepatitis-B vaccine in elderly. PATIENTS AND METHODS: In a clinical trial on 140 subjects aged ?40 years with a body mass index (BMI) <30 kg/m2, and without any co-morbid disease were recruited. Those who had negative hepatitis B core antibody (102 persons) were randomly allocated to two groups. The trial group received hepatitis B vaccine plus 200 mg zinc sulfate daily for 30 days and the control group received vaccine plus placebo. RESULTS: 52 of 102 people were female (51%). The two studied groups were comparable in terms of age, gender, and smoking habits. The mean antibody production in the intervention and control groups was 116.93 and 157.37 mIU/mL, respectively (p=0.22). No statistical differences were observed between the two groups in terms of proportion of people who were protected after vaccination (26.0% and 36.5% in people with and without zinc, respectively). CONCLUSIONS: This study revealed that zinc sulfate has no effect in level of immunity among elderly.
Authors: Clare F Hodkinson; Mary Kelly; H Denis Alexander; Ian Bradbury; Paula J Robson; Maxine P Bonham; Jacqueline M O'Connor; Charles Coudray; J J Strain; Julie M W Wallace Journal: J Gerontol A Biol Sci Med Sci Date: 2007-06 Impact factor: 6.053